RxDoctor Payments DataLook up a doctor →

Antonella Leary, MD

Gynecologic Oncology · Palm Beach Gardens, FLNPI 1730279670

Payments from drug & device makers

$8,355in general payments, 2019–2025

Across 352 payments — averaging $23.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • LSI Solutions Inc$700
  • Baxter Healthcare$534
  • AstraZeneca$426
  • Incyte Corporation$381
  • Merck$373
  • GSK$335
  • plus $5K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
LSI Solutions Inc4$700
Baxter Healthcare4$534
AstraZeneca(2 entities)25$426
Incyte Corporation17$381
Merck21$373
GSK20$335
Bayer19$334
Amgen20$327
Daiichi Sankyo Inc.14$315
Intuitive Surgical4$288
Seagen Inc.13$224
E.r. Squibb & Sons, L.L.C.13$218
Novartis12$215
Eisai Inc.8$191
Sanofi8$189
Bristol Myers Squibb9$161
Regeneron Healthcare Solutions, Inc.8$159
Pharmaessentia USA Corporation6$149
Davol Inc.1$148
Pfizer6$129
Johnson & Johnson7$127
AbbVie6$125
Adaptive Biotechnologies Corporation6$119
Genentech USA, Inc.5$116
Tempus AI, Inc5$116
Hologic Sales And Service, LLC2$114
Takeda Pharmaceuticals U.S.A., Inc.6$111
Momentis Surgical Inc.1$109
Tersera Therapeutics LLC4$92
Ipsen Biopharmaceuticals, Inc4$85
Jazz Pharmaceuticals Inc.5$78
Pharmacyclics LLC, An Abbvie Company3$64
Array Biopharma Inc3$59
Boehringer Ingelheim2$59
GE HealthCare2$57
Taiho Oncology, Inc.3$57
Dendreon Pharmaceuticals LLC3$56
Deciphera Pharmaceuticals Inc.2$51
Servier Pharmaceuticals LLC2$50
Octapharma USA, Inc.1$47
Puma Biotechnology, Inc.3$44
Stemline Therapeutics Inc.2$41
Heron Therapeutics, Inc.2$40
Beigene USA, Inc.2$40
Pharmacosmos Therapeutics Inc.1$39
Karyopharm Therapeutics Inc.2$38
Beone Medicines USA, Inc.2$38
Astellas Pharma US Inc2$37
Immunogen, Inc.2$36
EMD Serono, Inc.2$36
Dova Pharmaceuticals2$35
Sobi, Inc2$34
Coopersurgical, Inc.1$33
Clovis Oncology, Inc.2$31
Myriad Genetic Laboratories, Inc.2$31
Mirati Therapeutics, Inc.1$28
Rigel Pharmaceuticals, Inc.1$25
Legend Biotech USA Inc.1$23
Morphosys, US Inc.1$22
Mylan Institutional Inc.1$21

How this compares

$8,355 in reported general payments places this provider in the 50th percentile of 117 gynecologic oncology providers in Florida.

See all gynecologic oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$196,880
Medicare patients
279
Services billed
2,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Palm Beach Gardens

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →